We describe a case of serotonin syndrome secondary to clozapine withdrawal and concomitant use of
citalopram hydrobromide, a phenomenon that has been rarely reported.
This is a case report of a 47-year-old woman admitted to an academic medical center intensive
care unit with coma, hypersalivation, hyperreflexia, and stimulus-induced clonus. The patient
received a diagnosis of serotonin syndrome attributed to abrupt clozapine withdrawal with
concomitant use of citalopram. She improved only minimally with supportive treatment (intravenous
fluids, benzodiazapines, and withdrawal of selective serotonin-reuptake inhibitor) and received
cyproheptadine hydrochloride on her third day of symptoms. Four hours after she received the loading
dose of cyproheptadine, she was alert and oriented and at her baseline mental status, although some
Conclusions and Relevance
Serotonin syndrome can result from the abrupt withdrawal of a 5-hydroxytryptamine receptor 2A
antagonist from a treatment regimen that also includes a medication that increases serotonin
Clozapine is an atypical antipsychotic commonly used in the treatment of schizophrenia. Its efficacy is attributed to its antagonist actions at serotonin receptors (5-hydroxytryptamine receptor 2).1 The drug also antagonizes dopamine (D1 and D2) receptors and has significant antimuscarinic effects.1 The abrupt withdrawal of clozapine has been associated with cholinergic rebound and rapid onset of psychosis,1- 3 and less frequently with emergent dystonias and dyskinesias.4 There are rare case reports of abrupt clozapine withdrawal inducing serotonin syndrome with5 and without6 concomitant use of a serotonergic agent. Herein, we describe a case of serotonin syndrome that developed with the abrupt withdrawal of clozapine with concomitant use of citalopram hydrobromide, a selective serotonin reuptake inhibitor.
A 47-year-old schizophrenic woman presented with 7 days of nausea and vomiting and was hospitalized with presumed viral gastroenteritis. Owing to an inaccuracy on her accompanying medication list, her longstanding treatment with clozapine (100 mg nightly) was inadvertently discontinued while her longstanding treatment with citalopram (10 mg daily) was continued. Her gastrointestinal symptoms gradually improved with bowel rest, intravenous fluid, and intermittent antiemetics (ondansetron hydrochloride, promethazine hydrochloride, and metoclopramide hydrochloride) that were last administered on day 3 of her hospitalization, 48 hours before her clinical deterioration. On day 5 of her hospital stay, she was found to be unresponsive with inducible clonus of her lower extremities. She was afebrile, hemodynamically stable, and breathing spontaneously, but she was intubated for airway control and brought to the intensive care unit.
In the intensive care unit, her temperature was 37.1°C (98.8°F), her pulse rate was 80 to 120 beats per minute, her blood pressure was 113/59 mm Hg, and her oxygen saturation was 100% on a fraction of inspired oxygen of 65%. On further examination, she was found to be intermittently agitated without eye opening or purposeful movements, but she did withdraw all 4 extremities to pain. Her face was symmetric, and she had normal gag and cough. Hypersalivation was noted. She did blink both eyes to visual threat, and her pupils were reactive from 4 to 3 mm. She had moderate upper extremity and severe lower extremity spasticity with inducible clonus of her ankles bilaterally. Muscle stretch reflexes were 3+ with spread in her upper extremities and 4+ with spread in her lower extremities. The results of arterial blood gas analysis were normal, and the results of serum and urine toxicology studies were negative. All additional serologic test results, including those for complete blood count, chemistry, creatine kinase, liver and thyroid function, vitamin B12, folate, and lactate levels, were also normal. Urinalysis was unremarkable. The results of electrocardiography, computed tomography of the head, and magnetic resonance imaging/magnetic resonance angiography of the head and neck were normal. Continuous video electroencephalograms recorded for 24 hours showed diffuse slowing but no epileptiform activity. Citalopram and antiemetics were discontinued, and the patient was treated supportively with intravenous fluid and intermittent benzodiazapines for agitation. Her mental status improved minimally, and she was extubated after 48 hours. At 72 hours, she was minimally responsive and rarely following commands; however, her spasticity and clonus remained.
At this point, an extensive medication reconciliation revealed the omission of clozapine. This information, together with her failure to improve and negative workup, lead to the suspicion of serotonin syndrome. Therefore, she was treated with a loading dose of 6 mg of cyproheptadine hydrochloride through her nasogastric tube, followed by 2 mg every 4 hours for 24 hours. Four hours after the loading dose, she was fully alert and oriented and at her baseline mental status, although her hyperreflexia and clonus remained. She was discharged from the hospital several days later while still being treated with cyproheptadine, which was titrated down as her clozapine was titrated back up to her preadmission dose. Her hyperreflexia and clonus resolved within weeks of hospital discharge.
Abrupt withdrawal of clozapine has been associated with symptoms of “cholinergic rebound,” including nausea, vomiting, hypersalivation, diarrhea, diaphoresis, insomnia, and agitation, as well as rapid onset of psychosis.1- 4 There are comparatively fewer reports of serotonin syndrome associated with the withdrawal of the serotonin receptor antagonist clozapine.5,6 Although our patient exhibited some symptoms of cholinergic rebound (agitation and hypersalivation), we believe that her abrupt decline in arousal and the development of clonus and hyperreflexia were the result of serotonergic alteration7 secondary to clozapine withdrawal. Clozapine is a 5-hydroxytryptamine receptor 2A antagonist,8 and both acute and long-term clozapine use have been shown to downregulate the 5-hydroxytryptamine receptor 2A in the rat cerebral cortex.9 The abrupt discontinuation of the drug may therefore have led to a decrease in antagonism and upregulation of the receptor as shown by Huang and colleagues10 in their animal model.
In combination with the selective serotonin reuptake inhibitor citalopram, perhaps with additional influence from the antiemetics metoclopromide and ondansetron,7,11 this phenomenon may have been responsible for the serotonergic overload experienced by our patient. Treatment with cyproheptadine, an antihistamine with anticholinergic properties,12 which also antagonizes the 5-hydroxytryptamine receptor 2A,8 resulted in the normalization of our patient’s mental status within 4 hours and the resolution of her other symptoms over the next several weeks as clozapine was slowly reintroduced. Clinicians should be aware that abrupt withdrawal of clozapine (and perhaps any other serotonin receptor antagonist) in the presence of an agent that increases availability of serotonin may lead to serotonin syndrome.5 If the discontinuation of treatment with clozapine is desired, it should be gradually tapered off over several weeks, rather than abruptly discontinued, except in cases of emergency, such as agranulocytosis, and then only with close monitoring of the patient.
Accepted for Publication: January 10, 2013.
Corresponding Author: Dr Stevenson, Department of Pulmonary
Critical Care, Boston Medical Center, 72 E Concord St, R3, Boston, MA 02118 (firstname.lastname@example.org).
Published Online: June 10, 2013. doi:10.1001/jamaneurol.2013.95.
Author Contributions:Study concept and design: Stevenson, Schembri, Burns.
Acquisition of data: Stevenson.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: Stevenson.
Critical revision of the manuscript for important intellectual content: All
Study supervision: Schembri, Green, Burns.
Conflict of Interest Disclosures: None
Thank you for submitting a comment on this article. It will be reviewed by JAMA Neurology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.